In the tumor panel, increased promoter methylation was observed in BLU, CASP8, DCR2, CDH1, RASSF1A and RASSF2 (Table1), possibly providing the second hit for BLU, RARB and RASSF1A. The gene discussed is RASSF2; the disease is neoplasm.